Institut Català de la Salut
[Mora Buch R, Tomás Marín M] Advanced & Cell Therapy Services, Blood and Tissue Bank (BST), Barcelona, Spain. Advanced & Cell Therapy Services, Blood and Tissue Bank (BST), Barcelona, Spain. [Pasamar H] Advanced & Cell Therapy Services, Blood and Tissue Bank (BST), Barcelona, Spain. [Enrich E, Rudilla F] Grup de Recerca de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain. Immunogenetics and Histocompatibility Laboratory, Blood and Tissue Bank (BST), Barcelona, Spain. [Peña Gómez C] Barcelona Supercomputing Center, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-10-14T08:35:02Z
2025-10-14T08:35:02Z
2025-06-19
BK virus; HLA genotype; T cell donors
Virus BK; Genotipo HLA; Donantes de células T
Virus BK; Genotip HLA; Donants de cèl·lules T
Purpose: The increasing application of virus-specific T cell therapy for treating BK virus infections in immunocompromised patients highlights the necessity for rapid identification of compatible cell donors with optimal BK-specific T cell response. This study aims to characterize the BK virus-specific T cell response in relation to demographic factors, blood group, serological status, and HLA genotypes using samples from a cell donor registry. Methods: Peripheral blood mononuclear cells from cell donors were stimulated with peptide pools derived from VP1 and LTA proteins, and the IFN-γ production was analyzed using ELISpot and validated by flow cytometry. Results: Our findings provide an overview of the T cell response to BK virus proteins in healthy donors, revealing associations with demographic characteristics, RhD status, CMV or EBV serological status, and HLA alleles. Remarkably, RhD-negative, CMV-seronegative, and EBV-seronegative donors showed a major T cell response against BK virus proteins. Notably, certain HLA alleles were associated with either enhanced or diminished T cell response. Furthermore, our results suggest that HLA-B leader dimorphism, specifically the presence of threonine at position 2, influences the VP1-specific immune response, resulting in enhanced T cell activation. Conclusion: This study, beyond advancing our understanding of the relationship between donor characteristics and BK virus-specific T cell response, has significant implications for improving the selection of optimal cell donors for patient-specific adoptive therapy.
Artículo
Versión publicada
Inglés
Antígens HLA; Citomegalovirus; Poliomavirus; Genotip; Cèl·lules T; ORGANISMS::Viruses::DNA Viruses::DNA Tumor Viruses::Polyomaviridae::Polyomavirus::BK Virus; ORGANISMS::Viruses::DNA Viruses::Herpesviridae::Betaherpesvirinae::Cytomegalovirus; ORGANISMS::Viruses::DNA Viruses::DNA Tumor Viruses::Gammaherpesvirinae::Lymphocryptovirus::Herpesvirus 4, Human; ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes; PHENOMENA AND PROCESSES::Genetic Phenomena::Genotype; CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Surface::Histocompatibility Antigens::HLA Antigens; ORGANISMOS::virus::virus ADN::virus ADN tumorales::Polyomaviridae::poliomavirus::virus BK; ORGANISMOS::virus::virus ADN::Herpesviridae::Betaherpesvirinae::citomegalovirus; ORGANISMOS::virus::virus ADN::virus ADN tumorales::Gammaherpesvirinae::Lymphocryptovirus::Herpesvirus humano 4; ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T; FENÓMENOS Y PROCESOS::fenómenos genéticos::genotipo; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos de superficie::antígenos de histocompatibilidad::antígenos HLA
Springer
Journal of Clinical Immunology;45
https://doi.org/10.1007/s10875-025-01901-2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - VHIR [1655]